Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

262 results
Display

Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review

Kim MS, Choi CH, Kim TJ, Lee JW, Lee J, Bae DS, Kim BG

Malignant melanoma of the genital tract is a rare disease that is usually diagnosed by chance. When a definite diagnosis is delayed, the prognosis is very poor without standardized treatment....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Angiographically Documented Macular Ischemia after Single Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion

Lee KH, Kang EC, Koh HJ

This report describes a case of angiographically documented foveal avascular zone (FAZ) enlargement after a single intravitreal injection of bevacizumab for macular edema secondary to central retinal vein occlusion (CRVO)....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Update on immune checkpoint inhibitors in gynecological cancers

Heong V, Ngoi N, Tan DS

In recent years, progress in our understanding of immune-modulatory signaling pathways in immune cells and the tumor microenvironment (TME) has led to rejuvenated interest in cancer immunotherapy. In particular, immunotherapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea

Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, Koo JR, Park Y, Park YS, Shin JI, Yoo KH, Oh D

Atypical hemolytic uremic syndrome (aHUS) is a rare syndrome characterized by micro-angiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The major pathogenesis of aHUS involves dysregulation of the complement system....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)

Kim ES, Kim KO, Jang BI, Lee CK, Kim HJ, Lee KM, Kim YS, Eun CS, Jung SA, Yang SK, Lee J, Kim TO, Jung Y, Seo GS, Yoon SM, the IBD Study Group of the Korean Association for the Study of the Intestinal Diseases (KASID)

BACKGROUND/AIMS: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn's disease (CD)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis

Kim JH, Cheon JH

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Golimumab Therapy in Ulcerative Colitis

Moon W

Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry

Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, Jo DY, Chung J, Sohn SK, Lee JW

Paroxysmal nocturnal hemoglobinuria (PNH) is a progressive, systemic, life-threatening disease, characterized by chronic uncontrolled complement activation. A retrospective analysis of 301 Korean PNH patients who had not received eculizumab was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Emerging Therapies for Osteoporosis

McClung MR

Although several effective therapies are available for the treatment of osteoporosis in postmenopausal women and older men, there remains a need for the development of even more effective and acceptable...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Assessment of Patient Pain Experience during Intravitreal 27-Gauge Bevacizumab and 30-Gauge Ranibizumab Injection

Guler M, Bilgin B, Capkin M, Simsek A, Bilak S

PURPOSE: To compare pain scores of patients during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection procedures. METHODS: Seventy eyes of 70 patients who had not previously undergone intravitreal anti-vascular endothelial growth...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current and Emerging Biologics for Ulcerative Colitis

Park SC, Jeen YT

Conventional medical treatment for ulcerative colitis can have limited efficacy or severe adverse reactions requiring additional treatment or colectomy. Hence, different biological agents that target specific immunological pathways are being...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Drug Survival Rates of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

Kang JH, Park DJ, Lee JW, Lee KE, Wen L, Kim TJ, Park YW, Lee SS

We investigated the compliance of Korean patients using tumor necrosis factor (TNF) inhibitors to treat rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and identified potential predictors associated with treatment discontinuation....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Trastuzumab-Conjugated Liposome-Coated Fluorescent Magnetic Nanoparticles to Target Breast Cancer

Jang M, Yoon YI, Kwon YS, Yoon TJ, Lee HJ, Hwang SI, Yun BL, Kim SM

OBJECTIVE: To synthesize mesoporous silica-core-shell magnetic nanoparticles (MNPs) encapsulated by liposomes (Lipo [MNP@m-SiO2]) in order to enhance their stability, allow them to be used in any buffer solution, and to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment

Ahn YJ, Hwang HB, Chung SK

Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Serum Concentration of Vascular Endothelial Growth Factor after Bilateral Intravitreal Injection of Bevacizumab

Wang D, Choi KS, Lee SJ

PURPOSE: This study compared serum vascular endothelial growth factor (VEGF) concentration between patients given the bilateral and unilateral intravitreal injections of bevacizumab. METHODS: In a prospective manner, serum VEGF levels in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Injection of Intravitreal Drugs with Standard Care in Macular Edema Secondary to Branch Retinal Vein Occlusion

Lee K, Jung H, Sohn J

PURPOSE: To compare the long-term efficacy and safety of intravitreal triamcinolon with or without rescue laser therapy (intravitreal triamcinolone injection [IVTA] group), bevacizumab with or without rescue laser treatment (intravitreal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Safe Re-administration of Tumor Necrosis Factor-alpha (TNFalpha) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFalpha Therapy

Suh YS, Kwok SK, Ju JH, Park KS, Park SH, Yoon CH

There is no consensus on whether it is safe to re-administer tumor necrosis factor-alpha (TNFalpha) inhibitors in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) flared after withdrawal of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Anti-VEGF-refractory Exudative Age-related Macular Degeneration: Differential Response According to Features on Optical Coherence Tomography

Shin JY, Woo SJ, Ahn J, Park KH

PURPOSE: To describe optical coherence tomography (OCT) characteristics of neovascular age-related macular degeneration (AMD) patients refractory to intravitreal anti-vascular endothelial growth factor (VEGF) injections (ranibizumab, bevacizumab) and their responses to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Body Weight and Bone Density Changes in Patients with Ankylosing Spondylitis Receiving Anti-Tumor Necrosis Factor-alpha Treatment

Lee J, Jung M, Kim D, Lee S, Oh SK, Jo Y, Byun S, Nam K, Lee C

  • KMID: 2267771
  • Korean J Med.
  • 2013 Nov;85(5):489-494.
BACKGROUND/AIMS: To determine the changes in body weight and bone mineral density in patients with ankylosing spondylitis (AS) receiving anti-tumor necrosis factor-alpha (TNF-alpha) treatment. METHODS: Thirty-one patients with AS (25 males...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cetuximab Related Eyelash Elongations for Patients with Metastatic Rectum Carcinoma: Metabolic Complete Response

Urun Y, Utkan G

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr